Comparison of Helicobacter pylori eradication rate according to different PPI-based triple therapy--omeprazole, rabeprazole, esomeprazole and lansoprazole--
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Keum B. | - |
dc.contributor.author | Lee S.W. | - |
dc.contributor.author | Kim S.Y. | - |
dc.contributor.author | Kim J.M. | - |
dc.contributor.author | Choung R.S. | - |
dc.contributor.author | Yim H.J. | - |
dc.contributor.author | Jeen Y.T. | - |
dc.contributor.author | Lee H.S. | - |
dc.contributor.author | Chun H.J. | - |
dc.contributor.author | Um S.H. | - |
dc.contributor.author | Choi J.H. | - |
dc.contributor.author | Kim C.D. | - |
dc.contributor.author | Ryu H.S. | - |
dc.contributor.author | Hyun J.H. | - |
dc.date.available | 2020-11-03T16:47:33Z | - |
dc.date.issued | 2005-12 | - |
dc.identifier.issn | 1598-9992 | - |
dc.identifier.issn | 2233-6869 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/20071 | - |
dc.description.abstract | BACKGROUND/AIMS: Helicobacter pylori (H. pylori) is an important cause of various gastrointestinal diseases. H. pylori eradication is essential for the cure and prevention of associated diseases. Nowdays, proton pump inhibitor (PPI)-based triple therapy is the standard eradication regimen. The aims of this study were to compare the H. pylori eradication rate of different PPI-based triple therapies and to find out the factors influencing the eradication rate. METHODS: From May 2002 through February 2004, H. pylori infected patients were treated with the eradication regimen based on one of the four PPIs (omeprazole, rabeprazole, esomeprazole and lansoprazole) for 1 or 2 weeks. After two weeks, drug compliance, adverse effects, and smoking history during the eradication therapy were obtained. The follow-up H. pylori test was performed 4 weeks after the completion of therapy. The data were analyzed by Chi-square test and multiple logistic regression analysis. RESULTS: Overall eradication rate was 83.5%. There was no significant difference in eradication rate among four PPIs (p=0.379). Odds ratio (OR) for omeprazole and rabeprazole was 1.15 (95% CI 0.50-2.68); for omeprazole and esomeprazole, OR 1.63 (95% CI 0.68-3.89); and for omeprazole and lansoprazole, OR 1.13 (95% CI 0.50-2.56). Smoking habit, site of ulcer, and the duration of therapy affected the eradication rate significantly. CONCLUSIONS: The efficacy of four different PPIs for H. pylori eradication is similar to each other. Smoking, site of ulcer, and the duration of treatment have significant effects on eradication rates. | - |
dc.format.extent | 7 | - |
dc.language | 한국어 | - |
dc.language.iso | KOR | - |
dc.title | Comparison of Helicobacter pylori eradication rate according to different PPI-based triple therapy--omeprazole, rabeprazole, esomeprazole and lansoprazole-- | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.scopusid | 2-s2.0-33644930032 | - |
dc.identifier.bibliographicCitation | The Korean journal of gastroenterology, v.46, no.6, pp 433 - 439 | - |
dc.citation.title | The Korean journal of gastroenterology | - |
dc.citation.volume | 46 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 433 | - |
dc.citation.endPage | 439 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001108444 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordPlus | antiinfective agent | - |
dc.subject.keywordPlus | antiulcer agent | - |
dc.subject.keywordPlus | proton pump | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | comparative study | - |
dc.subject.keywordPlus | drug antagonism | - |
dc.subject.keywordPlus | drug combination | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | Helicobacter infection | - |
dc.subject.keywordPlus | Helicobacter pylori | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | microbiology | - |
dc.subject.keywordPlus | middle aged | - |
dc.subject.keywordPlus | Adult | - |
dc.subject.keywordPlus | Anti-Infective Agents | - |
dc.subject.keywordPlus | Anti-Ulcer Agents | - |
dc.subject.keywordPlus | Drug Therapy, Combination | - |
dc.subject.keywordPlus | Female | - |
dc.subject.keywordPlus | Helicobacter Infections | - |
dc.subject.keywordPlus | Helicobacter pylori | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Male | - |
dc.subject.keywordPlus | Middle Aged | - |
dc.subject.keywordPlus | Proton Pumps | - |
dc.subject.keywordAuthor | Proton pump inhibitor | - |
dc.subject.keywordAuthor | Helicobacter pylori | - |
dc.subject.keywordAuthor | Eradication rate | - |
dc.subject.keywordAuthor | 프로톤 펌프 억제제 | - |
dc.subject.keywordAuthor | 제균율 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.